These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35623354)

  • 21. Disabling a Type I-E CRISPR-Cas Nuclease with a Bacteriophage-Encoded Anti-CRISPR Protein.
    Pawluk A; Shah M; Mejdani M; Calmettes C; Moraes TF; Davidson AR; Maxwell KL
    mBio; 2017 Dec; 8(6):. PubMed ID: 29233895
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional characterization of diverse type I-F CRISPR-associated transposons.
    Roberts A; Nethery MA; Barrangou R
    Nucleic Acids Res; 2022 Nov; 50(20):11670-11681. PubMed ID: 36384163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Crystal structure of an anti-CRISPR protein, AcrIIA1.
    Ka D; An SY; Suh JY; Bae E
    Nucleic Acids Res; 2018 Jan; 46(1):485-492. PubMed ID: 29182776
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RNA Guide Complementarity Prevents Self-Targeting in Type VI CRISPR Systems.
    Meeske AJ; Marraffini LA
    Mol Cell; 2018 Sep; 71(5):791-801.e3. PubMed ID: 30122537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cas13d Is a Compact RNA-Targeting Type VI CRISPR Effector Positively Modulated by a WYL-Domain-Containing Accessory Protein.
    Yan WX; Chong S; Zhang H; Makarova KS; Koonin EV; Cheng DR; Scott DA
    Mol Cell; 2018 Apr; 70(2):327-339.e5. PubMed ID: 29551514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection.
    East-Seletsky A; O'Connell MR; Knight SC; Burstein D; Cate JH; Tjian R; Doudna JA
    Nature; 2016 Oct; 538(7624):270-273. PubMed ID: 27669025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cas13-induced cellular dormancy prevents the rise of CRISPR-resistant bacteriophage.
    Meeske AJ; Nakandakari-Higa S; Marraffini LA
    Nature; 2019 Jun; 570(7760):241-245. PubMed ID: 31142834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prophages are associated with extensive CRISPR-Cas auto-immunity.
    Nobrega FL; Walinga H; Dutilh BE; Brouns SJJ
    Nucleic Acids Res; 2020 Dec; 48(21):12074-12084. PubMed ID: 33219687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural and mechanistic insights into the inhibition of type I-F CRISPR-Cas system by anti-CRISPR protein AcrIF23.
    Ren J; Wang H; Yang L; Li F; Wu Y; Luo Z; Chen Z; Zhang Y; Feng Y
    J Biol Chem; 2022 Jul; 298(7):102124. PubMed ID: 35697070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-canonical inhibition strategies and structural basis of anti-CRISPR proteins targeting type I CRISPR-Cas systems.
    Yin P; Zhang Y; Yang L; Feng Y
    J Mol Biol; 2023 Apr; 435(7):167996. PubMed ID: 36754343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An enhanced assay to characterize anti-CRISPR proteins using a cell-free transcription-translation system.
    Wandera KG; Collins SP; Wimmer F; Marshall R; Noireaux V; Beisel CL
    Methods; 2020 Feb; 172():42-50. PubMed ID: 31121300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular basis of dual anti-CRISPR and auto-regulatory functions of AcrIF24.
    Kim GE; Lee SY; Birkholz N; Kamata K; Jeong JH; Kim YG; Fineran PC; Park HH
    Nucleic Acids Res; 2022 Oct; 50(19):11344-11358. PubMed ID: 36243977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Listeria Phages Induce Cas9 Degradation to Protect Lysogenic Genomes.
    Osuna BA; Karambelkar S; Mahendra C; Christie KA; Garcia B; Davidson AR; Kleinstiver BP; Kilcher S; Bondy-Denomy J
    Cell Host Microbe; 2020 Jul; 28(1):31-40.e9. PubMed ID: 32325050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector.
    Abudayyeh OO; Gootenberg JS; Konermann S; Joung J; Slaymaker IM; Cox DB; Shmakov S; Makarova KS; Semenova E; Minakhin L; Severinov K; Regev A; Lander ES; Koonin EV; Zhang F
    Science; 2016 Aug; 353(6299):aaf5573. PubMed ID: 27256883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structural and mechanistic insights into the CRISPR inhibition of AcrIF7.
    Kim I; Koo J; An SY; Hong S; Ka D; Kim EH; Bae E; Suh JY
    Nucleic Acids Res; 2020 Sep; 48(17):9959-9968. PubMed ID: 32810226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-CRISPRs: Protein Inhibitors of CRISPR-Cas Systems.
    Davidson AR; Lu WT; Stanley SY; Wang J; Mejdani M; Trost CN; Hicks BT; Lee J; Sontheimer EJ
    Annu Rev Biochem; 2020 Jun; 89():309-332. PubMed ID: 32186918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure of AcrVIA2 and its binding mechanism to CRISPR-Cas13a.
    Song G; Li X; Wang Z; Dong C; Xie X; Yan X
    Biochem Biophys Res Commun; 2022 Jul; 612():84-90. PubMed ID: 35512461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bacteriophage genome engineering with CRISPR-Cas13a.
    Guan J; Oromí-Bosch A; Mendoza SD; Karambelkar S; Berry JD; Bondy-Denomy J
    Nat Microbiol; 2022 Dec; 7(12):1956-1966. PubMed ID: 36316452
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A jumbo phage that forms a nucleus-like structure evades CRISPR-Cas DNA targeting but is vulnerable to type III RNA-based immunity.
    Malone LM; Warring SL; Jackson SA; Warnecke C; Gardner PP; Gumy LF; Fineran PC
    Nat Microbiol; 2020 Jan; 5(1):48-55. PubMed ID: 31819217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting of temperate phages drives loss of type I CRISPR-Cas systems.
    Rollie C; Chevallereau A; Watson BNJ; Chyou TY; Fradet O; McLeod I; Fineran PC; Brown CM; Gandon S; Westra ER
    Nature; 2020 Feb; 578(7793):149-153. PubMed ID: 31969710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.